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Editorial
Under-reported complications related to BMP use in spine 
surgery
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A  recent  review  article  and  editorial  in  the  Spine  Journal 
shows  that  in  13  industry-sponsored  trials  of  recombinant 
BMP-2 for spine applications in a total of 780 patients, not 
a single drug-related complication was reported (Carragee et 
al. 2011a, b). This contrasts with FDA databases and unspon-
sored case series showing several drug-related problems, such 
as dramatic local bone resorption or local swelling leading 
to airway obstruction. The review and the subsequent jaw-
dropping correspondence leaves little doubt that several of the 
industry-sponsored papers were deliberately deceitful. 
New methods commonly appear to work better in the hands 
of the inventor. This may be related to higher competence, e.g. 
by more careful patient selection. However, the risk of self-
delusion is of course high, when a lot of prestige is involved 
(as for the academic inventor) or when millions of dollars 
relate the investigator to the industry, as in many of the studies 
of BMP-2 in spine surgery. In contrast to spine studies, unfa-
vorable results with BMP-2 in tibial fractures seem to have 
been meticulously reported (Aro et al. 2011).
The BMP-2 spine affair illustrates the folly of grading stud-
ies for level of evidence, based on standardized criteria. The 
“level 1” trials may have been misleading, but the complica-
tion rates in “level 3” case series should have given reasons for 
thinking twice. There is no way to make good clinical deci-
sions based on standard criteria without critical thinking. But, 
alas, thinking clearly is so difficult. One of the problems is 
that we like good news, whereas reading about obstacles and 
complications makes no one happy (except those of us who 
enjoy a trace of academic sadism). Actually, Acta Orthopedica 
pioneered the reporting of BMP-related problems: one of the 
first case series (perhaps the very first) with a BMP for cervi-
cal spine surgery was published in Acta Orthopedica already 
in 1999 (Jeppsson et al.). The series had to be stopped due to a 
complete lack of effect in 3 of the first 4 patients. This did not 
reduce the general enthusiasm for BMPs, and the senior author 
went on to a moderately successful trial on lumbar spine (it 
was me). Acta Orthopedica also published very early animal 
work showing that BMPs could actually reduce net bone for-
mation (Jeppsson and Aspenberg 1996, Jeppsson et al. 1999). 
Again, this passed without much notice. Later, during the first 
years of BMP trials, many rumors circulated within the “BMP 
community” about problems with local swelling, and the first 
case of resorption of a vertebral body was published as early 
as in 1999 (Laursen et al.). Still, we all hoped that this was 
part of a learning curve, and we were afraid to throw out the 
baby with the bathwater. After all, John Charnely’s first 300 
cases with hip replacements largely failed, but in the end his 
technique became one of the greatest achievements in ortho-
pedics—ever. 
Current  thinking  mainly  suggests  that  the  problem  of 
investigator bias could be solved by publishing details of the 
authors’ economic ties to industry. The underlying thought is 
that economic support corrupts. But does it always? Should a 
study with good financial support automatically be regarded 
as less reliable? There may be a difference between studies 
initiated and performed by the industry and studies initiated 
by academic researchers but funded by the industry. In the 
latter case, an author may have a stronger position in discus-
sions with the company’s marketing department. Economic 
ties may carry a higher risk of bias, but after all, a wish for 
academic prestige may be an even more common cause of 
scientific misconduct than economic profit. Publishing of eco-
nomic ties might be a good idea, but it is more important that 
authors know that if they deceivingly omit serious complica-
tions, it may be the last paper they are ever able to publish.
However, the responsibility for possible over-use of BMP-2 
lies not only with sponsors, authors, and editors but also with 
readers and the orthopedic community as a whole. The early 
warnings  of  problems  related  to  BMPs,  and  the  published 
complications,  were  not  sufficiently  discussed  at  the  time, 
especially not at the many industry-sponsored satellite ses-
sions  held  at  academic  meetings.  Such  meetings  might  be 
more responsible for the spread of biased opinions than jour-
nal articles. Again, the orthopedic decision-maker has to rise 
above the level of just keeping a finger in the air to feel the 
latest trends. He or she must be an intellectual who doesn’t 
rush to introduce new techniques, but reads and thinks criti-
cally. This might become increasingly difficult now in the 
Nordic countries too, as private care and market thinking are 
gaining ground.
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